** Shares of gene therapy firm Bluebird Bio BLUE.O down 8.7% at $4.08 premarket
** BLUE says privately held UK company Ayrmid Ltd has not submitted binding proposal to acquire it and has not obtained necessary financing
** Co in March received non-binding offer from Ayrmid for up to $110.5 million
** BLUE adds it continues to be at significant risk of defaulting on its loan covenants
** Co's board reaffirms its recommendation in support of transaction with Carlyle CG.O and SK Capital, while recommending all stockholders tender into current agreement by May 2
** BLUE agreed to be taken private by Carlyle and SK Capital Partners at discount in February
** As of last close, stock has fallen 46.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.